Loss of heterozygosity at the TP53 gene: Independent occurrence from genetic instability events in node‐negative breast cancer

• Published in: International journal of cancer 1997-08, Vol.72 (4), p.599-603
• Main Authors: Lizard‐Nacol, Sarab, Riedinger, Jean‐Marc, Lizard, Gérard, Glasser, Anne‐Lise, Coudray, Nolwenn, Chaplain, Gilles, Guerrin, Jacques
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biological and medical sciences; Breast Neoplasms - genetics; Breast Neoplasms - pathology; DNA, Neoplasm - genetics; Female; Gene Amplification; Gene Deletion; Genes, p53; Gynecology. Andrology. Obstetrics; Heterozygote; Humans; Lymph Nodes - pathology; Mammary gland diseases; Medical sciences; Middle Aged; Oncogenes; Tumors
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/(SICI)1097-0215(19970807)72:4<599::AID-IJC8>3.0.CO;2-L

TP53 abnormalities have been reported as an early event in the process of cellular transformation of human breast cancers, and involved in mammary‐tumor evolution, from in situ to invasive disease. In this study, node‐negative (N−) tumors were examined for TP53 allelic loss in relation to different genetic instability events, including allelic loss at chromosome 17p13.3 and c‐H‐ras‐1 loci, as well as alteration of the c‐myc and c‐erbB‐2/neu oncogenes. TP53 allelic loss was analyzed to determine whether such an abnormality was the more important, among other genetic events, in the N− tumors, whether it appeared independently of these genetic events, and whether accumulation of genetic events arises in this group of breast tumors. Clinicopathological parameters were also examined. Loss of heterozygosity (LOH) at the TP53 gene appears the most frequent alteration detected (26% vs. 13%, 8%, 9% and 3% for LOH at D17S30 and c‐H‐ras‐1 loci, and amplification of c‐myc and c‐erbB‐2/neu respectively). There was no association between LOH at the TP53 locus and other genetic events. Among clinicopathological parameters, significant associations were observed only with estrogen‐receptor‐negative tumors (p = 0.05). Our results demonstrate that LOH at TP53 arises more frequently in the N− breast cancer, thus supporting earlier findings suggesting that TP53 abnormality has a role early in the pathogenesis of breast lesions. Moreover, the data indicate that accumulation of many genetic events occurs at a low level in N− breast tumors, and that TP53 abnormality occurs independently of these genetic events. Int. J. Cancer 72:599–603, 1997. © 1997 Wiley‐Liss, Inc.